Astec LifeSciences Limited has informed the Exchange regarding Board meeting held on July 28, 2025.
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astec LifeSciences' Board approved unaudited Q1 FY26 (quarter ended June 30, 2025) results, with revenue from operations rising to Rs. 9,108 lakhs from Rs. 6,937 lakhs a year ago — a strong ~31% year-on-year growth. Despite the revenue jump, the company stayed in the red with a net loss of Rs. 3,306 lakhs (standalone), though the loss was narrower than Rs. 3,974 lakhs in Q1 FY25. Operating margin improved sharply from -66.7% to -12.1%, signalling cost-side progress but still negative. The auditor (BSR & Co. LLP) issued an unmodified limited review opinion on both standalone and consolidated results. The company's debt-equity ratio climbed to 2.96 (from 1.58 a year ago), with negative DSCR and ISCR, and working capital is negative. The Board noted that the ongoing Rights Issue of up to Rs. 249.35 crore (at Rs. 890/share, 1:7 ratio) closed on the same day.
The strong revenue growth and narrowing losses are positives, but persistent net losses, a deteriorating debt-equity ratio above 2.9, and negative debt service coverage ratios keep the stock under earnings pressure. The Rs. 249 crore rights issue closing on the same day is a key near-term event that will dilute existing shareholders but strengthen the balance sheet.